Marshall Wace, LLP Crinetics Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $5.95 Million - $7.33 Million	141,204 New	141,204 $6.32 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $471,115 - $902,405	29,500 New	29,500 $877,000
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $7,631 - $12,597	-445 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $8,610 - $12,642	445 New	445 $12,000
Q2 2020 Aug 13, 2020	SELL	$13.04 - $23.23 $55,367 - $98,634	-4,246 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$11.52 - $26.46 $48,913 - $112,349	4,246 New	4,246 $62,000
Q4 2019 Feb 14, 2020	SELL	$15.24 - $25.09 $839,906 - $1.38 Million	-55,112 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$14.91 - $25.01 $311,231 - $522,058	20,874 Added 60.97%	55,112 $829,000
Q2 2019 Aug 14, 2019	BUY	$21.48 - $27.71 $3,780 - $4,876	176 Added 0.52%	34,238 $857,000
Q1 2019 May 14, 2019	BUY	$21.07 - $29.31 $717,686 - $998,357	34,062 New	34,062 $775,000

242

79.6M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.98B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.